Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …

Abstract Background Antibody–drug conjugates (ADCs) have complex molecular structures
and have been tested in numerous clinical trials. Therefore, understanding the mechanisms …

Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological
malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell …

Lymphomatoid papulosis (LyP) is a benign chronic often relapsing skin condition that
belongs to the CD 30‐positive cutaneous lymphoproliferative disorders. LyP typically …

In recent decades, therapy for acute myeloid leukemia (AML) has remained relatively
unchanged, with chemotherapy regimens primarily consisting of an induction regimen …

Background The safety and efficacy of brentuximab vedotin (BV), an antibody-drug
conjugate directed to the CD30 antigen, has been assessed in several trials in patients with …

Introduction Traditional cancer therapy has many disadvantages such as low selectivity and
high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance …